Senzime’s Year-end Bulletin 2017

Press release: Uppsala, February 16, 2018. Senzime AB’s (publ) year-end bulletin 2017 is now available on the company’s webbsite www.senzime.com.

"Now, Senzime takes a big step towards the market. We have unique, CE-approved medical technology systems ready to cost-effectively prevent millions of healthcare complications - every year. We have conducted many years of research and today have a number of distributor and license agreements in place. This financing will enable us to accelerate market rollout and will strengthen our position in negotiations with additional potential strategic partners," says Lena Söderström, President and CEO of Senzime.

Financial information fourth quarter 2017

  •  Net sales amounts to KSEK 15 (185)
  •  Income after financial items amounts to KSEK -3,671 (-3,572).
  •  Earnings per share before dilution amounts to SEK -0.09 (-0.10).

Financial information January - December 2017

  •  Net sales amounts to KSEK 189 (1,628)
  •  Income after financial items amounts to KSEK -13,027 (-9,412).
  •  Earnings per share before dilution amounts to SEK -0.33 (-0.34).

For further information, please contact:

Jessica Roxhed, CFO

Tel: +46 703-94 94 98, e-mail: jessica.roxhed@senzime.com 

TO THE EDITORS  

About Senzime  

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com 

This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on February 16th 2018.

Tags:

About Us

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com